迈向滤泡性淋巴瘤的无化疗方案
滤泡性淋巴瘤(FL)的治疗格局正因无化疗策略的出现而转变,这些策略挑战了传统以化疗为导向的模式,为新诊断和复发或难治(RR)患者提供了有希望的替代方案。现有数据支持从二线治疗开始采用完全无化疗方案,如利妥昔单抗-来那度胺(R2)或tafasitamab-R2;双特异性抗体(bsAbs)、布鲁顿酪氨酸激酶(BTK)抑制剂和嵌合抗原受体(CAR)T细胞疗法可作为第二次复发后的选择。未来,bsAbs(主要与来那度胺联合)可能作为一线或二线治疗,有望完全替代免疫化疗,而CAR T细胞疗法将在选定的高危患者中发挥作用。鉴于无化疗方案的不同毒性特征,需要更精细的预后评分,以便为患者分配合适的治疗,在疗效和安全性之间取得最佳平衡。
要点
- 现有数据支持从二线治疗开始采用完全无化疗方案,如R2或tafasitamab-R2。
- bsAbs、BTK抑制剂和CAR T细胞疗法可用于第二次复发后的患者。
- 未来bsAbs联合来那度胺可能作为一线或二线治疗,有望替代免疫化疗。
核心结论
- 滤泡性淋巴瘤的治疗正转向无化疗策略,现有数据支持从二线开始完全无化疗,未来bsAbs可能替代免疫化疗。
研究设计与样本
- 原文未报告
主要发现
- 现有数据支持从二线治疗开始采用完全无化疗方案,如利妥昔单抗-来那度胺(R2)或tafasitamab-R2。
- 双特异性抗体、BTK抑制剂和CAR T细胞疗法可作为第二次复发后的选择。
- 未来bsAbs主要与来那度胺联合,可能作为一线或二线治疗,有望完全替代免疫化疗;CAR T细胞疗法将在选定的高危患者中发挥作用。
关键数值与推荐
- 原文未报告
临床怎么用
- 原文未据此给出推荐
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo-free strategies that challenge the traditional chemo-oriented paradigms; this shift offers promising alternatives for both newly diagnosed and relapsed or refractory (RR) patients. Available data support a full chemo-free approach starting from second-line therapy, with rituximab-lenalidomide (R2) or tafasitamab-R2, whereas bispecific antibodies (bsAbs), Bruton's tyrosine kinase (BTK) inhibitors and chimeric antigen receptor (CAR) T-cell therapies are available options after second relapse. In the near future, bsAbs, mainly in combination with lenalidomide, will likely be employed as first- or second-line therapy, potentially fully replacing immunochemotherapy, whereas CAR T-cell therapy will play a role in selected high-risk patients. Given the different toxicity profiles of chemo-free options, refined prognostic scores are awaited so as to properly allocate patients to the most appropriate therapy with the best trade-off between efficacy and safety.
引用
- Luminari S, Barbieri E, Nizzoli ME, et al. Towards a chemo-free approach for follicular lymphoma. Br J Haematol. 2025. PMID: 40884311. doi:10.1111/bjh.70126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。